SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SCYNEXIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.66−0.01 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $43.28M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.38 (−39.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
SCYNEXIS INC grew revenue 489.8% to $19.22M over the twelve months to Jun 30, 2026.
Revenue
$19.22M
+489.8% vs. a year earlier
Operating income
-$22.60M
TTM Q2 2026
EPS, diluted
-$2.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $43.28M
- P/E ratio
- –
- Price to sales
- 2.25
- Price to book
- 0.65
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $19.22M
- Net income
- -$10.24M
- EPS, diluted
- -$2.15
- Book value per share
- $5.66
- Diluted shares
- 12M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$19.22M+489.8% YoY
Gross profit
–
Operating income
-$22.60M
Net income
-$10.24M
EPS, diluted
-$2.15
Free cash flow
–
Reported periodTrailing twelve months